Spero Therap (SPRO.US) Latest Stock News - Major News Analysis

Event Tracking

Dec19

Spero Therapeutics Partner GSK Resubmits tebipenem HBr NDA to FDA

13:00

Nov14

Spero Therap released FY2025 Q3 earnings on November 13 After-Market EST, with actual revenue of USD 5.442 M (forecast USD 0) and actual EPS of USD -0.1311 (forecast USD -0.25)

00:00

Spero Therap released FY2025 9 Months earnings on November 13 After-Market (EST), actual revenue USD 25.51 M, actual EPS USD -0.4119

00:00

Nov6

Spero Therapeutics to Release FY2025 Q3 Earnings on November 13 After-Market (EST), Forecast EPS -0.25 USD

00:25

Oct21

Spero Therapeutics and GSK Announce Positive Results for tebipenem HBr Phase III Trial

06:00

Aug12

Spero Therap released FY2025 Semi-Annual Earnings on August 12 After-Market (EST), Actual Revenue: USD 20.06M, Actual EPS: USD -0.2794

23:00

Schedules & Filings

Schedules

Filings

Nov13

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 5.442 M, Net Income -7.382 M, EPS -0.1311

Aug12

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 14.19 M, Net Income -1.7 M, EPS -0.0303

May13

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 5.874 M, Net Income -13.87 M, EPS -0.2503

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change